Latest Acquisitions News

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Sipa Resources has completed a key heritage survey at its Crown Gold Project near Kalgoorlie, clearing the way for initial drilling expected to begin next month. Meanwhile, assay results from its maiden drilling in South Australia are imminent.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Charter Hall Group reported a robust FY25 with a 7.3% rise in operating earnings per security and a surge in funds under management to $84.3 billion. The group’s strategic equity inflows and development pipeline expansion signal strong momentum heading into FY26.

Acumentis Group Limited reported a 4% revenue increase and a 35% jump in operating profit for FY25, driven by growth in corporate and private clients despite a government contract decline. The company declared a fully franked dividend and outlined a cautiously optimistic outlook for FY26.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion amid challenging global conditions, while profit after tax declined 14.6% to $77.1 million due to margin normalization and rising costs. The company completed three strategic acquisitions and declared a fully franked dividend of 12.5 cents per share.